Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, HCA Healthcare, Inc. (HCA) has a Wall Street consensus price target of $523.92, based on estimates from 46 covering analysts. With the stock currently trading at $529.70, this represents a potential downside of -1.1%. The company has a market capitalization of $118.45B.
Analyst price targets range from a low of $425.00 to a high of $635.00, representing a 40% spread in expectations. The median target of $525.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 30 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HCA trades at a trailing P/E of 18.7x and forward P/E of 17.5x. The forward PEG ratio of 0.83 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +2.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $659.11, with bear and bull scenarios of $537.74 and $866.62 respectively. Model confidence stands at 81/100, indicating high predictability in the company's fundamentals.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how HCA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonWall Street's consensus price target for HCA is $523.92, -1.1% from its current price of $529.7. The below-market target from 46 analysts suggests limited near-term appreciation.
HCA has a consensus rating of "Buy" based on 46 Wall Street analysts. The rating breakdown is predominantly bullish, with 30 Buy/Strong Buy ratings. The consensus 12-month price target of $523.92 implies -1.1% downside from current levels.
With a forward P/E of 17.5016x, HCA trades at a relatively low valuation. The consensus target of $523.92 implies -1.1% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $635 for HCA, while the most conservative target is $425. The consensus of $523.92 represents the median expectation. Our quantitative valuation model projects a bull case target of $867 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HCA is heavily covered by Wall Street, with 46 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 30 have Buy ratings, 14 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HCA stock forecast based on 46 Wall Street analysts shows a consensus price target of $523.92, with estimates ranging from $425 (bear case) to $635 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $659, with bear/bull scenarios of $538/$867.
Our quantitative valuation model calculates HCA's fair value at $659 (base case), with a bear case of $538 and bull case of $867. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 81/100.
HCA trades at a forward P/E ratio of 17.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on HCA, with 2 Sell ratings and a price target of $523.92 (-1.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HCA analyst price targets range from $425 to $635, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $523.92 consensus represents the middle ground. Our model's $538-$867 range provides an independent fundamental perspective.